Pulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Pulse Biosciences will report Q1 2026 results after the close on May 7, 2026, with analysts projecting EPS of ($0.32) and revenue of $0.40 million (the company beat EPS estimates in the prior quarter).
• Insiders have been net sellers recently—85,000 shares (~$1.99M) sold in the last 90 days (including a 5,000-share sale by Kevin Danahy)—even though corporate insiders still control 74.60% of the stock.
• Shares trade around $20 (market cap ~$1.37B) with a 52-week range of $12.56–$26.30, and analysts give a mixed view: consensus rating "Hold" with a $30 average target (two Buys, one Sell).

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) will likely be announcing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $0.40 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.06. On average, analysts expect Pulse Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pulse Biosciences Price Performance

Shares of NASDAQ PLSE opened at $20.21 on Thursday. The company has a market capitalization of $1.37 billion, a P/E ratio of -18.71 and a beta of 1.70. Pulse Biosciences has a one year low of $12.56 and a one year high of $26.30. The business's 50-day moving average price is $20.99 and its two-hundred day moving average price is $17.52.

Insider Activity

In related news, insider Kevin Patrick Danahy sold 5,000 shares of the company's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $23.64, for a total transaction of $118,200.00. Following the completion of the sale, the insider directly owned 43,298 shares of the company's stock, valued at approximately $1,023,564.72. This represents a 10.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 85,000 shares of company stock worth $1,994,400. Corporate insiders own 74.60% of the company's stock.

Institutional Trading of Pulse Biosciences

Several large investors have recently modified their holdings of the company. Tudor Investment Corp ET AL bought a new stake in shares of Pulse Biosciences during the 4th quarter worth $382,000. Inspire Investing LLC boosted its stake in Pulse Biosciences by 33.4% during the 4th quarter. Inspire Investing LLC now owns 34,192 shares of the company's stock valued at $469,000 after purchasing an additional 8,561 shares during the period. California State Teachers Retirement System boosted its stake in Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company's stock valued at $291,000 after purchasing an additional 3,991 shares during the period. Russell Investments Group Ltd. boosted its stake in Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock valued at $70,000 after purchasing an additional 619 shares during the period. Finally, ExodusPoint Capital Management LP boosted its stake in Pulse Biosciences by 14.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 25,122 shares of the company's stock valued at $345,000 after purchasing an additional 3,258 shares during the period. 76.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PLSE has been the subject of several recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Tuesday, April 21st. Oppenheimer reissued an "outperform" rating and issued a $30.00 target price on shares of Pulse Biosciences in a research report on Friday, February 20th. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a research report on Friday, February 6th. Finally, Wall Street Zen upgraded Pulse Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, February 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $30.00.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.